How to Treat Candida Glabrata and Prevent Its Recurrence

Candida glabrata (recently reclassified as Nakaseomyces glabrata, though most clinicians still use the older name) ranks among the most stubborn fungal infections because it resists the go-to antifungal most people have heard of: fluconazole. Treatment typically starts with an echinocandin for bloodstream infections or topical boric acid for vaginal infections, but the organism’s talent for dodging drugs and hiding inside immune cells makes recurrence a real and common problem. What follows is a practical walkthrough of what works, what does not, and why prevention demands more than just finishing a course of medication.

Why Standard Antifungals Often Fall Short

Most Candida infections people encounter are caused by C. albicans, which responds well to fluconazole and similar azole drugs. C. glabrata is a different beast. It carries an inherent low-level resistance to azoles, and clinical isolates frequently develop full-blown resistance through a specific genetic trick: gain-of-function mutations in a gene called CgPDR1. Those mutations crank up the production of efflux pumps, proteins that physically push azole drugs out of the fungal cell before they can do any damage. Research on clinical strains has identified several such mutations, and strains carrying them show not only decreased azole susceptibility but also increased ability to stick to host tissues, which could make them more dangerous overall.¹ Earlier work confirmed that the PDR1 gene is central to both acquired resistance (developing during treatment) and intrinsic resistance (present even before drug exposure), because deleting it made even previously resistant strains highly sensitive to fluconazole again.²

A systematic review covering data from 2011 to 2021 confirmed that azole resistance in C. glabrata is common and well described, and that resistance rates to echinocandins are also climbing. The organism does remain mostly susceptible to amphotericin B and flucytosine, but those drugs come with their own drawbacks in terms of side effects and availability.³

Treating Bloodstream and Invasive Infections

For invasive candidiasis, including candidemia (Candida in the bloodstream), echinocandins are the standard first-line therapy. The three available echinocandins are caspofungin, micafungin, and anidulafungin, and all are given intravenously. They work by blocking a different target than azoles: the enzyme that builds the fungal cell wall. Guidelines generally recommend starting an echinocandin immediately when C. glabrata is suspected or confirmed, with the option of stepping down to oral fluconazole later if susceptibility testing shows the isolate is sensitive.⁴

There is a catch, though. Studies in animal models suggest that standard echinocandin doses achieve a fungistatic effect against C. glabrata, meaning they stop the fungus from growing but do not kill it outright. Higher doses were needed to produce true fungicidal activity, particularly in hosts with weakened immune systems.⁵ This matters because patients who cannot mount their own immune response to finish off a suppressed fungal population are at higher risk of persistent or recurrent infection. In practice, this is why clinicians pay close attention to the patient’s immune status and sometimes extend treatment duration rather than simply following a fixed schedule.

Managing Vaginal Candida Glabrata Infections

Vaginal infections caused by C. glabrata are frustrating because the over-the-counter creams and oral fluconazole that clear most yeast infections frequently fail. The most commonly recommended first step is intravaginal boric acid, typically 600 mg inserted nightly for two to three weeks. In a study across two centers, this regimen cleared the infection both clinically and on culture in roughly two-thirds of symptomatic women.⁶

For the women whose infections persisted after boric acid, topical flucytosine cream applied nightly for 14 days was effective in about 90% of cases.⁶ Another approach that has shown significant clinical and microbiological improvement is a compounded combination of flucytosine and amphotericin B in a lubricating jelly base, applied vaginally once daily for 14 days.⁷ These are not off-the-shelf products; they have to be prepared by a compounding pharmacy, which can limit access and raise cost. Still, for refractory cases they represent some of the best-studied options available.

A practical note: boric acid capsules are widely available, but they should be used only vaginally and never swallowed, as boric acid is toxic if ingested. If you are dealing with a recurrent vaginal infection that has not responded to standard antifungals, getting a culture to confirm the species is essential. Many women cycle through fluconazole prescriptions without realizing the problem is C. glabrata rather than the more common C. albicans.

When Echinocandins Stop Working

Echinocandin resistance in C. glabrata is rarer than azole resistance but rising, and it is driven by a different mechanism: mutations in the FKS1 and FKS2 genes, which encode the drug’s target enzyme. In a large screen of over a thousand clinical isolates, 51 carried hot-spot mutations in those genes, and virtually all of them tested resistant to at least one echinocandin.⁸ Because echinocandin failure in this species is linked exclusively to these FKS substitutions, detecting them has become a surrogate way to flag resistant isolates in the lab.⁹

Experimental evolution studies have shown that C. glabrata can rapidly adapt to both fluconazole and anidulafungin. In laboratory experiments, multidrug resistance emerged through mutations in a limited set of genes, sometimes at moderate fitness costs, meaning the resistant strains were not crippled by their mutations and remained viable.¹⁰ This is worrying because it suggests resistance can arise quickly during a single course of treatment, not just over years of population-level drug pressure.

When an isolate is resistant to both azoles and echinocandins, clinicians are left with limited choices. Amphotericin B, a powerful but toxic antifungal, is often the fallback for systemic infections. Getting susceptibility results fast can steer treatment more effectively, and newer diagnostic tools are being developed to cut the turnaround time for resistance testing from at least 24 hours down to about six hours for bloodstream infections.¹¹

Ibrexafungerp and the Pipeline

One of the more promising additions to the antifungal toolkit is ibrexafungerp, a first-in-class oral drug that inhibits the same cell-wall enzyme the echinocandins target but does so at a different binding site. That distinction matters because it means ibrexafungerp retains activity against many echinocandin-resistant strains. Testing against 89 C. glabrata isolates carrying FKS mutations (all resistant to at least one echinocandin) showed good activity.¹² Laboratory kill-curve studies further demonstrated that ibrexafungerp produced a dramatic reduction in fungal counts at achievable drug concentrations, and the drug was active against both wild-type and echinocandin-resistant strains.¹³

The fact that ibrexafungerp is available as an oral medication is significant on its own. Echinocandins require intravenous administration, which means hospitalization or outpatient infusion visits. An effective oral option allows patients to complete treatment at home and opens up the possibility of step-down therapy from IV echinocandins to oral ibrexafungerp for susceptible infections. Broader reviews of in vitro data confirm activity against azole-resistant, echinocandin-resistant, and wild-type C. glabrata.¹⁴

The Biofilm Problem

Recurrence is not always about drug resistance in the traditional sense. C. glabrata readily forms biofilms, structured communities of cells encased in a self-produced matrix that shields them from both antifungals and the immune system. This is a major issue on indwelling medical devices like central venous catheters, urinary catheters, and prosthetic materials. Biofilm-embedded cells can tolerate drug concentrations many times higher than what kills free-floating cells.¹⁵

Removing the colonized device, when medically feasible, remains one of the most effective interventions. For patients who cannot have a catheter removed, alternative strategies include antifungal lock therapy (filling the catheter lumen with a concentrated antifungal solution), antimicrobial catheter coatings, and experimental approaches like natural antimicrobial peptides.¹⁵ Species-specific differences in biofilm architecture exist, driven by different genetic programs in C. glabrata compared to C. albicans or other non-albicans species, which adds another layer of complexity to managing these infections.¹⁶

How the Organism Hides and Why Infections Recur

C. glabrata has an unsettling ability to survive inside the very immune cells tasked with destroying it. After being engulfed by macrophages, the organism can replicate within them while causing surprisingly little damage and triggering only a muted immune response. It achieves this partly by preventing the macrophage from acidifying the compartment it is trapped in, essentially disabling one of the cell’s main killing mechanisms.¹⁷ The fungus keeps multiplying quietly until the macrophage eventually bursts, releasing organisms to infect new cells.¹⁸

This intracellular lifestyle helps explain why C. glabrata infections come back even after seemingly adequate treatment. Drugs that work in the blood or on mucosal surfaces may not reach effective concentrations inside macrophages where the organism is hiding. Metabolic flexibility adds to the problem: when glucose is scarce (as it is inside a macrophage), C. glabrata switches its metabolism to use alternative carbon sources through the glyoxylate cycle and gluconeogenesis pathways, keeping itself alive in conditions that would starve other fungi.¹⁹

The gastrointestinal tract also serves as a reservoir. C. glabrata colonizes the gut, and from there it can disseminate to other organs when conditions allow, particularly in hospitalized patients on antibiotics that strip away competing gut bacteria. Research has identified specific gut bacteria, including anaerobes and Enterococcus faecalis, that actually promote C. glabrata colonization and dissemination in the gastrointestinal tract.²⁰

Reducing Your Risk of Recurrence

Preventing recurrence means addressing the conditions that let C. glabrata gain a foothold in the first place. Diabetes is one of the best-documented risk factors: uncontrolled blood sugar creates a favorable environment for Candida species broadly, and the immunosuppressive effects of high glucose make it harder for the body to clear infection.²¹ Tightening glycemic control is not just good metabolic advice — it is a concrete antifungal strategy.

Broad-spectrum antibiotic use is another modifiable factor. Every course of broad-spectrum antibiotics reshapes the gut and vaginal microbiome, reducing the Lactobacillus populations and other commensal organisms that compete with Candida for space and resources. Limiting unnecessary antibiotic courses and choosing narrower-spectrum agents when possible can help preserve these natural defenses.

For vaginal recurrence specifically, interest is growing in probiotics and related approaches to restore a healthy microbiome. Certain probiotic strains have shown the ability to reduce Candida colonization and symptoms in clinical trials, though outcomes vary considerably depending on the specific strain, the Candida species involved, and the site of infection.²² Vaginal microbiota transplantation, analogous to fecal transplants for gut infections, is being explored as an emerging therapy, though it remains in early stages.²³ Neither probiotics nor microbiome transplantation should be considered proven standalone treatments at this point, but they represent a conceptual shift toward managing the environment the fungus lives in rather than only targeting the fungus itself.

Combination Strategies Still Under Investigation

Because C. glabrata resistance keeps narrowing the effective drug options, researchers are exploring drug combinations that restore or enhance the activity of existing antifungals. One laboratory study found that combining fluconazole with the immunosuppressant tacrolimus produced synergistic effects against C. glabrata, and the synergy was particularly strong against fluconazole-resistant isolates. Depending on which azole was paired with tacrolimus, synergistic interactions were observed in up to roughly three-quarters of resistant strains tested.²⁴

Another line of research has examined n-butylphthalide, a compound found in celery seed extract, as an adjuvant to fluconazole. In drug-resistant C. glabrata, it showed partial synergism with fluconazole by interfering with the efflux pumps (the same CDR1 and CDR2 pumps driven by the PDR1 mutations discussed earlier) and affecting mitochondrial respiratory chain enzymes.²⁵ These findings are still confined to lab experiments and have not been tested in people, but they illustrate the broader strategy of pairing a weakened antifungal with a second compound that blocks the fungus’s escape route.

Why Hospital Stewardship Programs Matter

For hospitalized patients, how quickly the right antifungal is started can make a meaningful difference. An antifungal stewardship program at one institution reduced the average time to appropriate treatment for candidemia, cutting it from about three and a half hours to just over two hours in the overall study population. The program also increased specialist consultations, connecting more patients with infectious disease experts and ophthalmologists (Candida can seed the eyes during bloodstream infection).²⁶

Stewardship also works in the other direction: minimizing unnecessary antifungal exposure across a hospital. Every patient who receives an echinocandin or azole they do not actually need applies selective pressure that nudges the local C. glabrata population toward resistance. The same logic applies individually. If you have been treated for a suspected yeast infection without a culture confirming the species and drug susceptibility, you might be doing more harm than good by cycling through antifungals that never targeted the actual organism.

Living Inside Immune Cells as a Long-Game Strategy

The intracellular survival of C. glabrata deserves one more look from a prevention angle, because it frames why simple drug exposure is sometimes insufficient. The organism does not just passively tolerate being inside macrophages. Research shows it actively inhibits the production of reactive oxygen species (the chemical weapons macrophages normally deploy), suppresses inflammatory cytokine release, and prevents the phagosome from acidifying.¹⁷ In essence, the fungus reprograms the immune cell into a safe house. Survival within macrophages has been proposed as a persistence strategy that could seed reinfection long after blood cultures turn negative.²⁷

This biological reality underscores why recurrence prevention cannot rely on drugs alone. Strengthening host defenses through managing underlying conditions, maintaining nutrition, and minimizing immunosuppression where possible all contribute to tipping the balance against an organism that is evolved to outlast a weakened immune system. For people dealing with repeated C. glabrata infections, working with an infectious disease specialist who understands the full range of treatment and prevention options is often the most productive step available.